BRPI0208870B8 - método de produção de polipeptídeos, vetor, composição farmacêutica, bem como método para diagnóstico de distrofia retinal - Google Patents
método de produção de polipeptídeos, vetor, composição farmacêutica, bem como método para diagnóstico de distrofia retinalInfo
- Publication number
- BRPI0208870B8 BRPI0208870B8 BRPI0208870A BR0208870A BRPI0208870B8 BR PI0208870 B8 BRPI0208870 B8 BR PI0208870B8 BR PI0208870 A BRPI0208870 A BR PI0208870A BR 0208870 A BR0208870 A BR 0208870A BR PI0208870 B8 BRPI0208870 B8 BR PI0208870B8
- Authority
- BR
- Brazil
- Prior art keywords
- retinal dystrophy
- syndrome
- disease
- polypeptides
- vector
- Prior art date
Links
- 208000032578 Inherited retinal disease Diseases 0.000 title abstract 4
- 208000032430 Retinal dystrophy Diseases 0.000 title abstract 4
- 201000006321 fundus dystrophy Diseases 0.000 title abstract 4
- 208000017532 inherited retinal dystrophy Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 3
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 abstract 1
- 208000027073 Stargardt disease Diseases 0.000 abstract 1
- 208000014769 Usher Syndromes Diseases 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000013399 early diagnosis Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0104712A FR2823221B1 (fr) | 2001-04-06 | 2001-04-06 | Sequences associees a la degenerescence retinienne et applications |
| PCT/EP2002/003810 WO2002081513A2 (en) | 2001-04-06 | 2002-04-05 | Disease-associated protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0208870A BR0208870A (pt) | 2004-04-27 |
| BRPI0208870B1 BRPI0208870B1 (pt) | 2016-01-12 |
| BRPI0208870B8 true BRPI0208870B8 (pt) | 2021-05-25 |
Family
ID=8862037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0208870A BRPI0208870B8 (pt) | 2001-04-06 | 2002-04-05 | método de produção de polipeptídeos, vetor, composição farmacêutica, bem como método para diagnóstico de distrofia retinal |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US7795387B2 (enExample) |
| EP (1) | EP1379657B1 (enExample) |
| JP (2) | JP4370428B2 (enExample) |
| KR (1) | KR100913258B1 (enExample) |
| CN (1) | CN1529753B (enExample) |
| AU (1) | AU2002312794B8 (enExample) |
| BR (1) | BRPI0208870B8 (enExample) |
| CA (1) | CA2443345C (enExample) |
| CZ (1) | CZ305800B6 (enExample) |
| EC (1) | ECSP024345A (enExample) |
| ES (1) | ES2597835T3 (enExample) |
| FR (1) | FR2823221B1 (enExample) |
| HU (1) | HU226307B1 (enExample) |
| IL (3) | IL158013A0 (enExample) |
| MX (1) | MXPA03009114A (enExample) |
| NO (1) | NO331277B1 (enExample) |
| NZ (1) | NZ528376A (enExample) |
| PL (1) | PL213658B1 (enExample) |
| RU (1) | RU2384586C2 (enExample) |
| SK (1) | SK288465B6 (enExample) |
| WO (1) | WO2002081513A2 (enExample) |
| ZA (1) | ZA200307403B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| US7261544B2 (en) | 2003-05-21 | 2007-08-28 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
| FR2870241B1 (fr) * | 2004-05-13 | 2015-02-27 | Novartis Ag | Facteur de viabilite des cones derive des batonnets ou rdcvf et applications |
| EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
| EP2281047B1 (en) | 2008-04-15 | 2020-04-08 | Genzyme Corporation | Methods to produce rod-derived cone viability factor (rdcvf) |
| JP5748223B2 (ja) * | 2008-09-10 | 2015-07-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子およびその使用 |
| EP2383286A1 (en) | 2010-04-30 | 2011-11-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treatment of retinal degenerative diseases |
| BR112014010091B1 (pt) | 2011-10-27 | 2022-11-08 | Wellstat Ophthalmics Corporation | Ácido nucleico, vetor viral, preparação farmacêutica, uso destes, método para produção de uma proteína rdcvf, e método in vitro ou ex vivo de secreção de uma proteína rdcvf a partir de uma célula |
| US20150038557A1 (en) | 2012-02-24 | 2015-02-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treatment of retinal degenerative diseases |
| US10004780B2 (en) | 2012-10-17 | 2018-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD) |
| EP3027646B1 (en) | 2013-07-31 | 2018-06-27 | Novartis AG | Novel selection vectors and methods of selecting eukaryotic host cells |
| JP6684343B2 (ja) | 2015-05-21 | 2020-04-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子の相乗組み合わせ及びその使用 |
| US10857240B2 (en) | 2016-01-05 | 2020-12-08 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of ocular disorders and blinding diseases |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| BR112018076674A2 (pt) * | 2016-10-11 | 2019-04-02 | Wellstat Ophthalmics Corporation | proteína de fusão entre o fator de viabilidade do cone derivado de bastonetes de forma curta e um peptídeo hidrofílico |
| US20230146121A1 (en) * | 2019-12-09 | 2023-05-11 | Chigenovo Co., Ltd. | Use of cyp4v2 and rdcvf in the manufacture of medicament |
| CN111733174B (zh) * | 2020-08-07 | 2021-02-09 | 北京大学第三医院（北京大学第三临床医学院） | 一种分离的核酸分子及其用途 |
| EP4366757A1 (en) * | 2021-07-07 | 2024-05-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies |
| CN113774019B (zh) * | 2021-08-11 | 2024-02-13 | 东南大学 | 一种脐带血间充质干细胞无血清培养基、培养方法及其应用 |
| US20240342313A1 (en) | 2023-03-30 | 2024-10-17 | Pharma Cinq, Llc | Vector encoding rod-derived cone viability factor and human igk signal sequence |
| US20260091133A1 (en) | 2024-09-27 | 2026-04-02 | Pharma Cinq, Llc | Rod-derived cone viability factor fusion protein |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4771036A (en) | 1986-02-10 | 1988-09-13 | Trustees Of Columbia University In The City Of New York | Method and ophthalmic composition for the prevention and reversal of cataracts |
| GB9701710D0 (en) * | 1997-01-28 | 1997-03-19 | Karobio Ab | Mammalian protein |
| US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
| FR2784030B1 (fr) | 1998-10-02 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine |
| FR2784898A1 (fr) | 1998-10-26 | 2000-04-28 | Univ Pasteur | Utilisation du gdnf pour le traitement de la degenerescence retinienne |
| EP1033405A3 (en) * | 1999-02-25 | 2001-08-01 | Ceres Incorporated | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby |
| EP1242443A4 (en) * | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| JP5748223B2 (ja) | 2008-09-10 | 2015-07-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子およびその使用 |
-
2001
- 2001-04-06 FR FR0104712A patent/FR2823221B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-05 CN CN028094700A patent/CN1529753B/zh not_active Expired - Lifetime
- 2002-04-05 US US10/473,008 patent/US7795387B2/en not_active Expired - Lifetime
- 2002-04-05 HU HU0303730A patent/HU226307B1/hu unknown
- 2002-04-05 CA CA2443345A patent/CA2443345C/en not_active Expired - Lifetime
- 2002-04-05 EP EP02737923.9A patent/EP1379657B1/en not_active Expired - Lifetime
- 2002-04-05 PL PL364681A patent/PL213658B1/pl unknown
- 2002-04-05 AU AU2002312794A patent/AU2002312794B8/en not_active Expired
- 2002-04-05 MX MXPA03009114A patent/MXPA03009114A/es active IP Right Grant
- 2002-04-05 KR KR1020037012934A patent/KR100913258B1/ko not_active Expired - Lifetime
- 2002-04-05 RU RU2003130638/13A patent/RU2384586C2/ru active
- 2002-04-05 JP JP2002579898A patent/JP4370428B2/ja not_active Expired - Lifetime
- 2002-04-05 ES ES02737923.9T patent/ES2597835T3/es not_active Expired - Lifetime
- 2002-04-05 NZ NZ528376A patent/NZ528376A/en not_active IP Right Cessation
- 2002-04-05 CZ CZ2003-2706A patent/CZ305800B6/cs not_active IP Right Cessation
- 2002-04-05 WO PCT/EP2002/003810 patent/WO2002081513A2/en not_active Ceased
- 2002-04-05 SK SK1223-2003A patent/SK288465B6/sk unknown
- 2002-04-05 IL IL15801302A patent/IL158013A0/xx unknown
- 2002-04-05 BR BRPI0208870A patent/BRPI0208870B8/pt not_active IP Right Cessation
- 2002-11-19 EC EC2002004345A patent/ECSP024345A/es unknown
-
2003
- 2003-09-18 IL IL158013A patent/IL158013A/en unknown
- 2003-09-23 ZA ZA200307403A patent/ZA200307403B/en unknown
- 2003-10-03 NO NO20034452A patent/NO331277B1/no not_active IP Right Cessation
-
2007
- 2007-04-25 US US11/739,734 patent/US8071745B2/en not_active Expired - Fee Related
- 2007-04-25 US US11/739,739 patent/US8114849B2/en not_active Expired - Fee Related
-
2009
- 2009-03-04 JP JP2009050689A patent/JP4571695B2/ja not_active Expired - Lifetime
- 2009-06-11 IL IL199316A patent/IL199316A/en active IP Right Grant
-
2012
- 2012-01-11 US US13/348,435 patent/US8518695B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/348,383 patent/US8394756B2/en not_active Expired - Fee Related
-
2013
- 2013-06-04 US US13/909,764 patent/US8957043B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208870A (pt) | Proteìna associada à doença | |
| Esteves et al. | Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology | |
| CY1119197T1 (el) | Μεθοδος παροχης νοσο-ειδικων μοριων και στοχων δeσμευσης | |
| MY169492A (en) | Improved protofibril selective antibodies and the use thereof | |
| MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
| Adav et al. | Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues | |
| AU2003270643A1 (en) | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence | |
| MX2010004319A (es) | Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide. | |
| DE602007014210D1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| WO2008042024A3 (en) | Neuroactive fragments of app | |
| BR112023001456A2 (pt) | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase | |
| Scheuren et al. | Hallmarks of frailty and osteosarcopenia in prematurely aged PolgA (D257A/D257A) mice | |
| Duerson et al. | Detergent‐insoluble EAAC1/EAAT3 aberrantly accumulates in hippocampal neurons of Alzheimer's disease patients | |
| CA2995310A1 (en) | Compounds for inducing tissue formation and uses thereof | |
| DE69724619D1 (de) | Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können | |
| AU2016310553A1 (en) | Compounds for inducing tissue formation and uses thereof | |
| AU2021254631A1 (en) | Compounds for inducing tissue formation and uses thereof | |
| NO20064989L (no) | Sulfonamidforbindelser for behandling av neurodegenerative lidelser | |
| WO2005113586A3 (en) | Disease-associated proteins | |
| Bayat et al. | Further delineation of facioaudiosymphalangism syndrome: description of a family with a novel NOG mutation and without hearing loss | |
| ATE547431T1 (de) | Single-chain-antikörper gegen den 37 kda/67 kda lamininrezeptor als werkzeuge zur diagnose und therapie von prionerkrankungen und krebs, deren herstellung und verwendung | |
| BRPI0408077A (pt) | composições e métodos para prevenção e tratamento de doenças relacionadas com endotoxina e condições | |
| JO3046B1 (ar) | اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها. | |
| Vasilopoulou et al. | Proteasome fate in aging and proteinopathies | |
| WO2004111086A3 (fr) | ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) , UNIVERSITE DE STRASBOURG (FR) Free format text: TRANSFERIDO POR FUSAO DE: UNIVERSITE LOUIS PASTEUR |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/04/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2717 DE 31-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |